The IgA nephropathy treatment dilemma

Kidney International

Volumn 69, Issue 11, 2006, Pages 1939-1944

  Appel, G B ^a   Waldman, M ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

ACE inhibitors; Cardiovascular disease; Glomerulonephritis; IgA nephropathy; Immunosuppression

Indexed keywords

ALKYLATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; ENALAPRIL; FATTY ACID; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; IMMUNOSUPPRESSIVE AGENT; LOSARTAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEGA 3 FATTY ACID; PREDNISONE; STEROID; TRANDOLAPRIL;

ANTIHYPERTENSIVE THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DRUG COST; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; PATHOGENESIS; PATIENT SELECTION; PRIORITY JOURNAL; RENAL PROTECTION; RISK FACTOR; SHORT SURVEY; TONSILLECTOMY; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

GLOMERULONEPHRITIS, IGA; HUMANS;

EID: 33745270017     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000434     Document Type: Short Survey

References (35)

1. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663.
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
3. Nishitani Y, Iwano M, Yamaguchi Y et al. Fibroblast-specific protein 1 is a specific prognostic marker for renal survival in patients with IgAN. Kidney Int 2005; 68: 1078-1085.
4. Bartosik LP, Lajoie G, Sugar L et al. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38: 728-735.
5. Donadio JV, Bergstralh EJ, Grande JP et al. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant 2002; 17: 1197-1203.
6. Myllymaki J, Honkanen T, Syrjanen J et al. Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant 2005; 20: 89-95.
7. Kanno Y, Okada H, Saruta T et al. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin Nephrol 2000; 54: 360-365.
8. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994; 23: 247-254.
9. Praga M, Gutierrez E, Gonzalez E et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583.
10. Russo D, Pisani A, Balletta MM et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33: 851-856.
11. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124.
12. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269.
13. Bianchi S, Bigazzi R, Caiazza A et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41: 565-570.
14. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 1999; 51: 147-152.
15. Hotta O, Miyazaki M, Furuta T et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 2001; 38: 736-743.
16. Xie Y, Nishi S, Ueno M et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003; 63: 1861-1867.
17. Donadio JV, Grande JP. The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin Nephrol 2004; 24: 225-243.
18. Hamazaki T, Tateno S, Shishido H. Eicosapentaenoic acid and IgA nephropathy. Lancet 1984; 1: 1017-1018.
19. Bennett WM, Walker RG, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial. Clin Nephrol 1989; 31: 128-131.
20. Pettersson EE, Rekola S, Berglund L et al. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. Clin Nephrol 1994; 41: 183-190.
21. Donadio Jr JV, Bergstralh EJ, Offord KP et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994; 331: 1194-1199.
22. Donadio Jr JV, Grande JP, Bergstralh EJ et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 1999; 10: 1772-1777.
23. Donadio Jr JV, Larson TS, Bergstralh EJ et al. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 2001; 12: 791-799.
24. Katafuchi R, Ikeda K, Mizumasa T et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis 2003; 41: 972-983.
25. Pozzi C, Bolasco PG, Fogazzi GB et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999; 353: 883-887.
26. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157-163.
27. Samuels JA, Strippoli GF, Craig JC et al. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology (Carlton) 2004; 9: 177-185.
28. Goumenos DS, Davlouros P, El Nahas AM et al. Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study. Nephron Clin Pract 2003; 93: C58-C68.
29. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-148.
30. Tumlin JA, Hennigar RA. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol 2004; 24: 256-268.
31. Maes BD, Oyen R, Claes K et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65: 1842-1849.
32. Chen X, Chen P, Cai G et al. A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy. Zhonghua Yi Xue Za Zhi 2002; 82: 796-801.
33. Tang S, Leung JC, Chan LY et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68: 802-812.
34. Frisch G, Lin J, Rosenstock J et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20: 2139-2145.
35. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.